×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
RVMD – revolution medicines, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
RVMD
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/24
04:25 pm
rvmd
Revolution Medicines to Participate in TD Cowen 46th Annual Health Care Conference [Yahoo! Finance]
Low
Report
Revolution Medicines to Participate in TD Cowen 46th Annual Health Care Conference [Yahoo! Finance]
2/24
04:05 pm
rvmd
Revolution Medicines to Participate in TD Cowen 46th Annual Health Care Conference
Low
Report
Revolution Medicines to Participate in TD Cowen 46th Annual Health Care Conference
2/24
12:42 pm
rvmd
Is Revolution Medicines (RVMD) Share Price Lagging Behind Its Long Term Surge? [Yahoo! Finance]
Low
Report
Is Revolution Medicines (RVMD) Share Price Lagging Behind Its Long Term Surge? [Yahoo! Finance]
2/24
01:36 am
rvmd
JPMorgan Signals High Conviction Ahead of Revolution Medicines (RVMD) Readout [Yahoo! Finance]
Low
Report
JPMorgan Signals High Conviction Ahead of Revolution Medicines (RVMD) Readout [Yahoo! Finance]
2/18
04:17 pm
rvmd
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026 [Yahoo! Finance]
Low
Report
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026 [Yahoo! Finance]
2/18
04:05 pm
rvmd
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026
Low
Report
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026
2/17
08:42 am
rvmd
Revolution Medicines (NASDAQ:RVMD) had its "overweight" rating reaffirmed by analysts at Benchmark Co..
Medium
Report
Revolution Medicines (NASDAQ:RVMD) had its "overweight" rating reaffirmed by analysts at Benchmark Co..
2/11
11:03 am
rvmd
Revolution Medicines, Inc. (RVMD) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript [Seeking Alpha]
Medium
Report
Revolution Medicines, Inc. (RVMD) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript [Seeking Alpha]
Date
Time
Symbol
Company Name
Action
%Chg
11/5/2025
04:02 pm
RVMD
revolution medicines, inc.
MISS
Report
3.4%
revolution medicines, inc.
8/6/2025
04:02 pm
RVMD
revolution medicines, inc.
MISS
Report
-4.7%
revolution medicines, inc.
5/7/2025
04:02 pm
RVMD
revolution medicines, inc.
MISS
Report
11.3%
revolution medicines, inc.
2/26/2025
04:02 pm
RVMD
revolution medicines, inc.
MISS
Report
-3.5%
revolution medicines, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/17
04:19 pm
rvmd
Form SCHEDULE 13G/A Revolution Medicines, Filed by: BAKER BROS. ADVISORS LP
Low
Report
Form SCHEDULE 13G/A Revolution Medicines, Filed by: BAKER BROS. ADVISORS LP
2/10
05:30 pm
rvmd
Form 4 Revolution Medicines, For: Feb 06 Filed by: GOLDSMITH MARK A
Low
Report
Form 4 Revolution Medicines, For: Feb 06 Filed by: GOLDSMITH MARK A
2/10
11:20 am
rvmd
Form SCHEDULE 13G/A Revolution Medicines, Filed by: WELLINGTON MANAGEMENT GROUP LLP
Low
Report
Form SCHEDULE 13G/A Revolution Medicines, Filed by: WELLINGTON MANAGEMENT GROUP LLP
2/9
08:53 am
rvmd
Form SCHEDULE 13G/A Revolution Medicines, Filed by: Farallon Capital Partners, L.P.
Low
Report
Form SCHEDULE 13G/A Revolution Medicines, Filed by: Farallon Capital Partners, L.P.
1/23
04:31 pm
rvmd
Form 4 Revolution Medicines, For: Jan 21 Filed by: Cislini Jeff
High
Report
Form 4 Revolution Medicines, For: Jan 21 Filed by: Cislini Jeff
1/21
04:23 pm
rvmd
Form 144 Revolution Medicines, Filed by: Cislini Jeff
Low
Report
Form 144 Revolution Medicines, Filed by: Cislini Jeff
1/9
04:21 pm
rvmd
Form 4 Revolution Medicines, For: Jan 07 Filed by: Horn Margaret A
Low
Report
Form 4 Revolution Medicines, For: Jan 07 Filed by: Horn Margaret A
1/9
04:20 pm
rvmd
Form 4 Revolution Medicines, For: Jan 07 Filed by: Anders Jack
Low
Report
Form 4 Revolution Medicines, For: Jan 07 Filed by: Anders Jack
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/29
Revolution Medicines Announces Publication of Scientific Paper Describing Anti-Tumor Immunity Induced by SHP2 Inhibitor in Preclinical Cancer Models
8.7%
3/18 Form SEC STAFF LETTER Revolution Medicines, 7.6%
4/16 Bill.com Holdings (NASDAQ: RVMD) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $27.00 price target on the stock. 6.6%
2/24 Form SC 13G Revolution Medicines, Filed by: Cormorant Asset Management, LP 4.5%
2/14 Form 4 Revolution Medicines, For: Feb 12 Filed by: Kelsey Stephen Michael 3.8%
2/18 Revolution Medicines Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares 3.3%
3/20 Form 8-K Revolution Medicines, For: Mar 18 3.1%
4/21 Form 8-K Revolution Medicines, For: Apr 17 2.6%
2/12 Form 3 Revolution Medicines, For: Feb 12 Filed by: GOEDDEL DAVID V 2.4%
4/17 Bill.com Holdings (NASDAQ: RVMD) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 1.7%
3/18 Form SEC STAFF LETTER Revolution Medicines, 7.6%
4/16 Bill.com Holdings (NASDAQ: RVMD) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $27.00 price target on the stock. 6.6%
2/24 Form SC 13G Revolution Medicines, Filed by: Cormorant Asset Management, LP 4.5%
2/14 Form 4 Revolution Medicines, For: Feb 12 Filed by: Kelsey Stephen Michael 3.8%
2/18 Revolution Medicines Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares 3.3%
3/20 Form 8-K Revolution Medicines, For: Mar 18 3.1%
4/21 Form 8-K Revolution Medicines, For: Apr 17 2.6%
2/12 Form 3 Revolution Medicines, For: Feb 12 Filed by: GOEDDEL DAVID V 2.4%
4/17 Bill.com Holdings (NASDAQ: RVMD) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 1.7%
TOP News Decliners
3/12
Form SEC STAFF LETTER Revolution Medicines,
-17.9%
5/1 Bill.com Holdings (NASDAQ: RVMD) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $38.00 price target on the stock. -5.7%
2/20 Form 4 Revolution Medicines, For: Feb 18 Filed by: Exter Neil -3.9%
2/14 Form SC 13G/A Revolution Medicines, Filed by: Boxer Capital, LLC -2.3%
3/30 Form 10-K Revolution Medicines, For: Dec 31 -1.9%
3/18 Revolution Medicines Announces Issuance of U.S. Patent Covering Compositions of Matter for its Clinical-Stage SHP2 Inhibitor Program -1.6%
2/19 Revolution Medicines Joins Amgen and Mirati in Quest for New Type of Cancer Drugs [Yahoo! Finance News] -0.9%
3/9 New Clinical Trial Exploring Revolution Medicines’ Investigational SHP2 Inhibitor RMC-4630 in Combination with an ERK Inhibitor Announced by Netherlands Cancer Institute -0.4%
2/13 Form SC 13G Revolution Medicines, Filed by: Boxer Capital, LLC -0.3%
5/1 Bill.com Holdings (NASDAQ: RVMD) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $38.00 price target on the stock. -5.7%
2/20 Form 4 Revolution Medicines, For: Feb 18 Filed by: Exter Neil -3.9%
2/14 Form SC 13G/A Revolution Medicines, Filed by: Boxer Capital, LLC -2.3%
3/30 Form 10-K Revolution Medicines, For: Dec 31 -1.9%
3/18 Revolution Medicines Announces Issuance of U.S. Patent Covering Compositions of Matter for its Clinical-Stage SHP2 Inhibitor Program -1.6%
2/19 Revolution Medicines Joins Amgen and Mirati in Quest for New Type of Cancer Drugs [Yahoo! Finance News] -0.9%
3/9 New Clinical Trial Exploring Revolution Medicines’ Investigational SHP2 Inhibitor RMC-4630 in Combination with an ERK Inhibitor Announced by Netherlands Cancer Institute -0.4%
2/13 Form SC 13G Revolution Medicines, Filed by: Boxer Capital, LLC -0.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: